Atopic dermatitis (AD), also known as eczema, is chronic inflammatory skin condition caused by heterogenous factors and manifesting across a range of severities from mild to moderate and severe. AD patients experience periods of flare (worsening of disease symptoms) and periods of remission (fewer symptoms or periods of clear skin). The flare symptoms, including dry skin, rash, skin redness, and pruritis, take a significant toll on the QoL, mental health, and activities of daily life for AD patients. These repeated flare cycles also challenge HCPs to adjust treatment options. For many mild to moderate AD patients, this cycle is a life-long, frustrating journey occurring when standard of care (SOC) topical therapy fails to manage symptoms, or their use is limited by tolerability issues.

SOC treatments for mild to moderate AD include topical forms of corticosteroid, calcineurin inhibitors, and a phosphodiesterase 4 (PDE4) inhibitor. The recent approval of a topical Janus kinase (JAK) inhibitor holds promise that new treatment options could reduce unmet need and improve the patient journey.

• In mild to moderate AD patients, which QoL factors do you commonly discuss, particularly when flares occur?
• How might a topical JAK inhibitor improve the patient journey for mild to moderate AD patients?

Atopic dermatitis (AD), also known as eczema, is chronic inflammatory skin condition caused by heterogenous factors and manifesting across a range of severities from mild to moderate and severe. AD patients experience periods of flare (worsening of disease symptoms) and periods of remission (fewer symptoms or periods of clear skin). The flare symptoms, including dry skin, rash, skin redness, and pruritis, take a significant toll on the QoL, mental health, and activities of daily life for AD patients. These repeated flare cycles also challenge HCPs to adjust treatment options. For many mild to moderate AD patients, this cycle is a life-long, frustrating journey occurring when standard of care (SOC) topical therapy fails to manage symptoms, or their use is limited by tolerability issues.



SOC treatments for mild to moderate AD include topical forms of corticosteroid, calcineurin inhibitors, and a phosphodiesterase 4 (PDE4) inhibitor. The recent approval of a topical Janus kinase (JAK) inhibitor holds promise that new treatment options could reduce unmet need and improve the patient journey.

• In mild to moderate AD patients, which QoL factors do you commonly discuss, particularly when flares occur?


• How might a topical JAK inhibitor improve the patient journey for mild to moderate AD patients?

Atopic dermatitis (AD), also known as eczema, is chronic inflammatory skin condition caused by heterogenous factors and manifesting across a range of severities from mild to moderate and severe. AD patients experience periods of flare (worsening of disease symptoms) and periods of remission (fewer symptoms or periods of clear skin). The flare symptoms, including dry skin, rash, skin redness, and pruritis, take a significant toll on the QoL, mental health, and activities of daily life for AD patients. These repeated flare cycles also challenge HCPs to adjust treatment options. For many mild to moderate AD patients, this cycle is a life-long, frustrating journey occurring when standard of care (SOC) topical therapy fails to manage symptoms, or their use is limited by tolerability issues.



SOC treatments for mild to moderate AD include topical forms of corticosteroid, calcineurin inhibitors, and a phosphodiesterase 4 (PDE4) inhibitor. The recent approval of a topical Janus kinase (JAK) inhibitor holds promise that new treatment options could reduce unmet need and improve the patient journey.

• In mild to moderate AD patients, which QoL factors do you commonly discuss, particularly when flares occur?


• How might a topical JAK inhibitor improve the patient journey for mild to moderate AD patients?

Atopic dermatitis (AD), also known as eczema, is chronic inflammatory skin condition caused by heterogenous factors and manifesting across a range of severities from mild to moderate and severe. AD patients experience periods of flare (worsening of disease symptoms) and periods of remission (fewer symptoms or periods of clear skin). The flare symptoms, including dry skin, rash, skin redness, and pruritis, take a significant toll on the QoL, mental health, and activities of daily life for AD patients. These repeated flare cycles also challenge HCPs to adjust treatment options. For many mild to moderate AD patients, this cycle is a life-long, frustrating journey occurring when standard of care (SOC) topical therapy fails to manage symptoms, or their use is limited by tolerability issues.



SOC treatments for mild to moderate AD include topical forms of corticosteroid, calcineurin inhibitors, and a phosphodiesterase 4 (PDE4) inhibitor. The recent approval of a topical Janus kinase (JAK) inhibitor holds promise that new treatment options could reduce unmet need and improve the patient journey.

• In mild to moderate AD patients, which QoL factors do you commonly discuss, particularly when flares occur?


• How might a topical JAK inhibitor improve the patient journey for mild to moderate AD patients?

Atopic dermatitis (AD), also known as eczema, is chronic inflammatory skin condition caused by heterogenous factors and manifesting across a range of severities from mild to moderate and severe. AD patients experience periods of flare (worsening of disease symptoms) and periods of remission (fewer symptoms or periods of clear skin). The flare symptoms, including dry skin, rash, skin redness, and pruritis, take a significant toll on the QoL, mental health, and activities of daily life for AD patients. These repeated flare cycles also challenge HCPs to adjust treatment options. For many mild to moderate AD patients, this cycle is a life-long, frustrating journey occurring when standard of care (SOC) topical therapy fails to manage symptoms, or their use is limited by tolerability issues.



SOC treatments for mild to moderate AD include topical forms of corticosteroid, calcineurin inhibitors, and a phosphodiesterase 4 (PDE4) inhibitor. The recent approval of a topical Janus kinase (JAK) inhibitor holds promise that new treatment options could reduce unmet need and improve the patient journey.

• In mild to moderate AD patients, which QoL factors do you commonly discuss, particularly when flares occur?


• How might a topical JAK inhibitor improve the patient journey for mild to moderate AD patients?